Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Pfizer Begins 2018 With Two Deals, Including ALS Tie-Up With Sangamo

Executive Summary

In addition to its latest collaboration with Sangamo, Pfizer also teams with Arvinas on protein-degradation therapies. AstraZeneca sells off four mature products to ANI, while Summit enhances its antibiotic capabilities with Discuva buyout and out-licenses Latin American rights to ridinilazole.

Advertisement

Related Content

Pfizer Buys Option For Vivet In Latest Gene Therapy Tie-Up
Finance Watch: VC Investment Soars In Q1, Putting Biopharma On Track For A Record Year
Gilead Partners With Sangamo For Gene Editing As It Builds Up Kite's Cell Therapy Platform
Finance Watch: Another Mega-Round As Moderna Bucks Biopharma's IPO Trend
Mallinckrodt Reduces Acthar Reliance With $1.2bn Sucampo Buy
Genexine Seals I-O Licensing Deal With I-Mab, Builds Momentum
Roche Ramps Up Cancer Portfolio With $1.7bn Ignyta Buy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC100132

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel